Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 5.92 | 4.03 | — | — | 5.12 | — | 0.93 | — | — | — | — | — | — | 3.34 | — | — | — | — | — | — | 2.42 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 46.52 | 25.85 | 59.36 | 75.33 | 120.20 | — | — | — | — | — | — | 706.90 | — | 1.23 | — | 179.81 | 57.10 | 65.06 | 109.88 | 26.50 | 1.30 |
| — | — | — | — | — | — | — | — | — | — | — | +293.1% | — | -98.1% | — | +578.5% | +4279.7% | -37.4% | +33.4% | -16.9% | -99.7% | |
| P/B Ratio | 0.76 | 2.20 | 3.21 | 2.98 | 3.86 | 2.95 | 2.42 | 10.43 | 6.04 | — | — | — | — | 27.50 | — | 65.03 | 11.64 | 13.72 | 8.11 | 5.82 | 3.76 |
| — | -25.3% | +32.7% | -71.4% | -36.0% | — | — | — | — | — | — | — | — | +100.4% | — | +1017.3% | +209.5% | -36.6% | -38.2% | -54.6% | -70.1% | |
| P/FCF | 42.43 | — | — | — | 19.20 | — | 1.13 | — | — | — | — | — | — | 2.40 | — | — | — | — | — | — | 1.34 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | 2.96 | — | — | — | — | — | — | 1.71 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 6.29 | — | 1.17 | — | — | — | — | — | — | 3.06 | — | — | — | — | — | — | 1.74 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -423.8% | 100.0% | -118.2% | 3251.8% | -3704.0% | — | — | — | — | — | — | 100.0% | — | 63.0% | 8523.2% | -4640.5% | 100.0% | -3513.1% | -2555.7% | -409.0% | 68.5% |
| — | — | — | — | — | — | — | — | — | — | — | +102.2% | — | +101.8% | +433.5% | -1034.7% | +45.9% | -502.4% | -519.6% | -883.6% | -31.5% | |
| Operating Margin | -11910.1% | -2890.4% | -5839.9% | -4424.0% | -6403.7% | — | — | — | — | — | — | -61759.4% | — | 39.2% | 13518.8% | -7005.8% | -1716.2% | -5207.6% | -3734.2% | -684.6% | 54.0% |
| — | — | — | — | — | — | — | — | — | — | — | -781.5% | — | +100.8% | +462.0% | -923.4% | -3279.3% | -469.3% | -504.4% | -571.8% | +102.6% | |
| Net Margin | 721.9% | 622.4% | -5562.3% | -3501.1% | 2337.3% | — | — | — | — | — | — | -64450.0% | — | 36.8% | 13634.9% | -7056.0% | -1742.2% | -5323.6% | -3792.6% | -692.4% | 53.8% |
| — | — | — | — | — | — | — | — | — | — | — | -813.4% | — | +100.7% | +459.5% | -919.0% | -3336.4% | -479.7% | -511.5% | -566.3% | +102.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.6% | 15.0% | -56.3% | -34.9% | 21.4% | -47.6% | 101.7% | -82.9% | 371.2% | — | — | — | -1277.6% | 205.9% | — | -175.6% | -132.4% | -124.5% | -53.3% | -32.5% | 49.3% |
| — | +131.5% | -155.4% | +57.9% | -94.2% | — | — | — | +129.0% | — | — | — | -865.0% | +265.4% | — | -439.4% | -368.6% | -215.2% | -139.3% | -223.5% | +199.7% | |
| ROA | 4.1% | 4.2% | -15.6% | -10.9% | 5.7% | -12.9% | 21.5% | -9.8% | 35.5% | -9.9% | -11.5% | -11.4% | -12.4% | 13.8% | -23.0% | -20.8% | -20.5% | -21.8% | -16.8% | -13.3% | 20.5% |
| — | +132.4% | -172.4% | -10.9% | -83.9% | -30.0% | +287.5% | +13.6% | +386.9% | -172.1% | +50.1% | +45.5% | +39.7% | +163.0% | -37.0% | -56.4% | -200.1% | -29.9% | -53.5% | -155.0% | +254.6% | |
| ROIC | -90.3% | -20.9% | -19.8% | -17.9% | -21.6% | -23.9% | -26.2% | -34.5% | -41.7% | -44.4% | -74.6% | -111.4% | -201.1% | 285.6% | -348.9% | — | — | — | -1368.2% | — | 160.4% |
| — | +12.6% | +24.6% | +48.2% | +48.2% | +46.2% | +64.9% | +69.0% | +79.3% | -115.5% | +78.6% | — | — | — | +74.5% | — | — | — | -5483.8% | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.88 | 1.64 | 3.04 | 1.88 | 1.95 | 2.65 | 1.77 | 6.65 | 3.91 | — | — | — | — | 9.42 | — | 15.08 | 1.13 | 3.35 | 0.96 | 0.37 | 0.25 |
| — | -38.2% | +71.2% | -71.8% | -50.1% | — | — | — | — | — | — | — | — | +181.2% | — | +3929.4% | +351.5% | +654.7% | +247.5% | +60.4% | +12.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | 4.17 | — | — | — | — | — | — | 0.63 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.56 | 2.11 | 1.65 | 2.56 | 2.30 | 1.57 | 2.11 | 0.94 | 1.12 | 1.38 | 1.68 | 1.78 | 2.71 | 3.23 | 1.82 | 2.28 | 3.03 | 2.35 | 3.20 | 3.69 | 3.79 |
| — | +34.4% | -22.0% | +172.4% | +104.2% | +14.1% | +25.8% | -47.2% | -58.4% | -57.3% | -7.8% | -21.9% | -10.5% | +37.0% | -43.1% | -38.4% | -20.3% | -41.1% | -39.3% | -36.3% | -43.6% | |
| Quick Ratio | 2.56 | 2.11 | 1.65 | 2.56 | 2.30 | 1.57 | 2.11 | 0.94 | 1.12 | 0.89 | 1.25 | 1.48 | 2.47 | 3.16 | 1.82 | 2.28 | 3.03 | 2.35 | 3.20 | 3.69 | 3.79 |
| — | +34.4% | -22.0% | +172.4% | +104.2% | +77.0% | +68.6% | -36.5% | -54.5% | -71.8% | -31.2% | -35.1% | -18.3% | +34.1% | -43.1% | -38.4% | -20.3% | -41.1% | -39.3% | -36.3% | -43.6% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -7.60 | -6.92 | -9.24 | -10.22 | 15.54 | -36.23 | -36.33 | -33.74 | -42.19 | -61.13 | -66.98 | 91.94 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MCRB stock.
Seres Therapeutics, Inc.'s current P/E is 5.9x. The average P/E over the last 2 quarters is 4.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Seres Therapeutics, Inc.'s current operating margin is -11910.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Seres Therapeutics, Inc.'s business trajectory between earnings reports.